NCT03486561Unknown4 期
Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 发起方
- OBS Pakistan
- 入组人数
- 2,000
- 主要终点
- Efficacy: Reduction in frequency of Angina with Ranolazine
研究概览
简要总结
The rationale of MIDA trial is to determine efficacy and tolerability of ranolazine molecule among Pakistan population and obtain firsthand knowledge about the molecule ranolazine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with diagnosis of coronary artery disease (CAD)
- •Patients present with the symptoms of stable angina after withdrawn from other antianginal drugs and given the required background therapy for at least 7 days will be qualified for entering this study and performing 1st ETT qualifying test
- •Patients developed exercise-induced ECG ischemiai during two qualifying exercise treadmill testsii.
- •Willing and able to provide a written informed consent
排除标准
- •• Factors that might compromise ECG or ETT interpretation
- •Patients with resting ST-segment depression ≥ 1mm in any lead
- •Left bundle-branch block
- •Patients implanted with pacemaker
- •Patients under Digitalis therapy
- •Patients with family history of (or congenital) long QT syndrome
- •Patients with congenital heart disease
- •Patients with uncorrected valvular heart disease
- •Patients with unstable angina, or MI, or coronary revascularization procedure ≤ 2 months prior enter this study
- •Female who is pregnant/lactating or planning to be pregnant, or female of childbearing potential* who is not using medically recognized method of contraception
- •*Other than those who have been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal.
- •Patients are under any one of the following conditions:
- •New York Heart Association (NYHA) Class III or Class IV congestive heart failure (CHF)
- •QTc > 450 msec at screening
- •Active myocarditis, pericarditis, hypertrophic cardiomyopathy
- •Uncontrolled hypertension (defined as SBP > 180 mmHg) Voltage criteria for left ventricular hypertrophy in the absence of repolarization abnormalities will not be exclusion criteria
- •Use of any investigational product ≤ 4 weeks prior to screening
- •Patients with severe hepatic disease (e.g., liver cirrhosis)
- •Patients with impaired renal function (defined as serum Cr >1.5 mg/dl)
- •Patients with any condition or disease which is considered not suitable for this study by investigator
研究组 & 干预措施
Ranolazine
Other
Ranolazine was approved by the U.S. Food and Drug Administration in 2006 in 500 mg and 1000 mg extended-release doses, advising 500 mg BID as a starting dose and 1000 mg BID as maximum dose
干预措施: Ranolazine (Drug)
结局指标
主要结局
Efficacy: Reduction in frequency of Angina with Ranolazine
时间窗: 24 weeks
To determine reduction in frequency of Angina with Ranolazine
次要结局
- Safety: Proportion of participants experiencing an adverse event (AE)(24 weeks)
研究者
相似试验
已完成
不适用
Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial IschemiaMicrovascular Coronary Dysfunction (MCD)NCT01342029Cedars-Sinai Medical Center142
已完成
2 期
Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial IschemiaAcute Myocardial IschemiaCoronary Artery DiseaseNCT01797484Universitätsklinikum Hamburg-Eppendorf20
已完成
3 期
Ranolazine and Pulmonary HypertensionAnginaPulmonary Arterial HypertensionNCT01174173Northwestern University11
已完成
2 期
Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic CardiomyopathyHCM - Hypertrophic Non-Obstructive CardiomyopathyNCT03953989IRCCS San Raffaele26
已完成
3 期
Ranolazine Implantable Cardioverter-Defibrillator TrialNonischemic CardiomyopathyHeart FailureIschemic CardiomyopathyNCT01215253University of Rochester1,012